Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.44 |
| ▸ | MLNR | O43193 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397693 | 0.88 | KDM4E (0.40) | CHRM3MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4391985 | 0.84 | CXCR4 (0.37) | CXCR4CHRM3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4391981 | 0.82 | MAPT (0.45) | CXCR4CHRM3MEN1KMT2AMAPT | |
| SCHEMBL4401054 | 0.82 | HTT (0.40) | CHRM3KMT2AALDH1A1TP53POLB | |
| SCHEMBL4401979 | 0.79 | DRD4 (0.41) | MLNRCHRM3MEN1KMT2AMAPT | |
| SCHEMBL4400761 | 0.79 | KMT2A (0.44) | CXCR4MLNRCHRM3MEN1KMT2A | |
| SCHEMBL4396219 | 0.79 | CHRM3 (0.49) | CXCR4MLNRCHRM3 | |
| SCHEMBL4397564 | 0.78 | CASR (0.49) | CHRM3MEN1KMT2AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4399450 | 0.77 | CASR (0.44) | MEN1KMT2ATP53 | |
| SCHEMBL4397695 | 0.75 | CHRM3 (0.37) | MLNRCHRM3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | CXCR4 273/4885MLNR 871/4885CHRM3 79/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | CXCR4 401/4885MLNR 532/4885CHRM3 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.